SEC 13F Intelligence

Managers / Q4 2020 · view latest →

Versant Venture Management, LLC

CIK 0001560009 · ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO, CA, 94104 · 650-233-7877

Reported Value
$963M
Q4 2020
Positions
12
Filings on Record
30
2019–present window
Filed
Feb 16, 2021
original filing

Summary

Versant Venture Management, LLC reported $963M in U.S.-listed holdings across 12 positions for Q4 2020.

The portfolio is heavily concentrated: Crispr Therapeutics alone accounts for 48.3% of reported value.

Compared with Q3 2020, the fund opened 2 new positions and exited 1.

Portfolio Metrics

Turnover
+8.5%
vs prior filed quarter
Top-10 Concentration
+99.6%
share of reported value
Largest Position
+48.3%
Crispr Therapeutics
New / Exited
2 / 1
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $202.0BQ4 ’18Q1 ’19: $303.6BQ2 ’19: $343.2BQ3 ’19: $258.5BQ4 ’19: $331.8BQ4 ’19Q1 ’20: $364.6BQ2 ’20: $696.1BQ4 ’20: $963MQ1 ’21: $513MQ1 ’21Q2 ’21: $302MQ3 ’21: $242MQ4 ’21: $187MQ1 ’22: $100MQ1 ’22Q2 ’22: $65MQ3 ’22: $59MQ4 ’22: $48MQ1 ’23: $48MQ1 ’23Q2 ’23: $84MQ3 ’23: $188MQ4 ’23: $389MQ1 ’24: $103MQ1 ’24Q2 ’24: $77MQ3 ’24: $64MQ4 ’24: $87MQ1 ’25: $60MQ1 ’25Q2 ’25: $82MQ3 ’25: $212MQ4 ’25: $151MQ1 ’26: $141MQ1 ’26filingsflow.com

Portfolio Composition

By security type
Other: 63.1%Common Stock: 36.9%
  • Other · 63.1% · $608M
  • Common Stock · 36.9% · $355M

Quarter-over-Quarter Changes full breakdown →

vs Q3 2020 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
Inari Medical, Inc.NEW+2.30M2.30M+$201M$201M
Aligos Therapeutics, Inc.NEW+3.29M3.29M+$91M$91M
Second Sight Medical Products, Inc.SOLD OUT−561.6K0−$484,000$0
2JQGritstone Oncology, Inc.ADDED+1.35M4.45M+$9M$18M
OCULOcular Therapeutix, Inc.TRIMMED−750.0K1.47M+$13M$30M
ADVMCHFAdverum Biotechnologies, Inc.TRIMMED−2.00M5.00M−$18M$54M
Aprea Therapeutics, Inc.TRIMMED−427.9K1.43M−$38M$7M
CRISPR Therapeutics AGTRIMMED−591.2K3.04M+$162M$466M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q4 2020

12 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1CRISPR Therapeutics AGCommon Shares48.34%$466M3.04M
2Inari Medical, Inc.Common Stock20.83%$201M2.30M
3Aligos Therapeutics, Inc.Common Stock9.45%$91M3.29M
4ADVMCHFAdverum Biotechnologies, Inc.history →Common Stock5.63%$54M5.00M
5Flexion Therapeutics, Inc.Common Stock4.60%$44M3.84M
6OCULOcular Therapeutix, Inc.history →Common Stock3.15%$30M1.47M
7CRNXCrinetics Pharmaceuticals, Inc.history →Common Stock2.98%$29M2.03M
8AKROAkero Therapeutics, Inc.history →Common Stock2.08%$20M777.7K
92JQGritstone Oncology, Inc.history →Common Stock1.82%$18M4.45M
10Aprea Therapeutics, Inc.Common Stock0.73%$7M1.43M
11CymaBay Therapeutics, Inc.Common Stock0.32%$3M543.8K
12CLVSEURClovis Oncology, Inc.Common Stock0.05%$489,000101.9K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$141M8May 5, 202613F-HRchanges · EDGAR ↗
Q4 2025$151M7Feb 12, 202613F-HRchanges · EDGAR ↗
Q3 2025$212M9Nov 10, 202513F-HRchanges · EDGAR ↗
Q2 2025$82M8Aug 11, 202513F-HRchanges · EDGAR ↗
Q1 2025$60M7May 7, 202513F-HRchanges · EDGAR ↗
Q4 2024$87M7Feb 12, 202513F-HRchanges · EDGAR ↗
Q3 2024$64M6Nov 8, 202413F-HRchanges · EDGAR ↗
Q2 2024$77M8Aug 7, 202413F-HRchanges · EDGAR ↗
Q1 2024$103M7May 3, 202413F-HRchanges · EDGAR ↗
Q4 2023$389M7Feb 8, 202413F-HRchanges · EDGAR ↗
Q3 2023$188M8Nov 3, 202313F-HRchanges · EDGAR ↗
Q2 2023$84M8Aug 9, 202313F-HRchanges · EDGAR ↗
Q1 2023$48M7May 11, 202313F-HRchanges · EDGAR ↗
Q4 2022$48M7Feb 9, 202313F-HRchanges · EDGAR ↗
Q3 2022$59M8Nov 10, 202213F-HRchanges · EDGAR ↗
Q2 2022$65M8Aug 11, 202213F-HRchanges · EDGAR ↗
Q1 2022$100M10May 10, 202213F-HRchanges · EDGAR ↗
Q4 2021$187M10Feb 11, 202213F-HRchanges · EDGAR ↗
Q3 2021$242M11Nov 12, 202113F-HRchanges · EDGAR ↗
Q2 2021$302M11Aug 12, 202113F-HRchanges · EDGAR ↗
Q1 2021$513M11May 7, 202113F-HRchanges · EDGAR ↗
Q4 2020$963M12Feb 16, 202113F-HRchanges · EDGAR ↗
Q3 2020Under review11Nov 12, 202013F-HRchanges · EDGAR ↗
Q2 2020$696.1B12Jul 20, 202013F-HRchanges · EDGAR ↗
Q1 2020$364.6B9Apr 28, 202013F-HRchanges · EDGAR ↗
Q4 2019$331.8B7Jan 21, 202013F-HRchanges · EDGAR ↗
Q3 2019$258.5B8Oct 8, 201913F-HRchanges · EDGAR ↗
Q2 2019$343.2B9Jul 12, 201913F-HRchanges · EDGAR ↗
Q1 2019$303.6B9Apr 5, 201913F-HRchanges · EDGAR ↗
Q4 2018$202.0B10Jan 22, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.